Applied Genetic Technologies Corporation announced the appointment of Michael Goldstein, M.D., M.B.A. as Chief Medical Officer (CMO) effective as of December 1, 2016. Dr. Goldstein will be responsible for leading the company’s clinical trials, providing medical oversight, and contributing to the overall strategic direction of the company. AGTC’s current Vice President and CMO, Jeffrey D. Chulay, M.D., DTM&H, will remain with the company as Executive Director of Clinical Strategy. Prior to joining AGTC, Dr. Goldstein held multiple roles of increasing responsibility with Eleven Biotherapeutics, including as Chief Medical Officer and Vice President of Clinical Research, where he worked with Eleven’s team to bring a novel treatment for dry eye disease from early research to a completed pivotal trial.